Puma Biotechnology Inc - Company Profile

Powered by

All the data and insights you need on Puma Biotechnology Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Puma Biotechnology Inc Strategy Report

  • Understand Puma Biotechnology Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Puma Biotechnology Inc: Overview

Select Item

Puma Biotechnology Inc (Puma) is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer. The company develops and commercializes drug candidates, namely, PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. The company’s pipeline portfolio also encompasses investigational candidates for various indications such as adjuvant breast cancer, gastric cancer, metastatic breast cancer and HER2-positive breast cancer and other cancers. Puma in-licenses its drug candidates and advances its development through clinical testing and for commercial use. Puma manufacture and distribute its products through the third party contractors. Puma is headquartered in Los Angeles, California, the US.

 Gain a 360-degree view of Puma Biotechnology Inc and make more informed decisions for your business Gain a 360-degree view of Puma Biotechnology Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 10880 Wilshire Blvd., Suite 2150, Los Angeles, California, 90024
Website www.pumabiotechnology.com
Telephone 1 424 2486500
No of Employees 185
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange PBYI (NASD)
Revenue (2022) $235.6M 3.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 1079450% (2022 vs 2021)
Market Cap* $254.1M
Net Profit Margin (2022) XYZ 134.4% (2022 vs 2021)
* As of and is in US$
View Puma Biotechnology Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Puma Biotechnology Inc premium industry data and analytics

70+

Clinical Trials

Determine Puma Biotechnology Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Puma Biotechnology Inc’s relevant decision makers and contact details.

50+

Catalyst Calendar

Proactively evaluate Puma Biotechnology Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Pipeline Drugs

Identify which of Puma Biotechnology Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Sales & Consensus Forecasts

Understand the current and future drug revenue for Puma Biotechnology Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Marketed Drugs

Understand Puma Biotechnology Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Puma Biotechnology Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Product:
Neratinib - Early Stage HER2-Overexpressed/Amplified Breast Cancer, HER2-Positive
Pipeline Portfolio:
XYZ
XYZ
XYZ
Understand Puma Biotechnology Inc portfolio and identify potential areas for collaboration Understand Puma Biotechnology Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Puma Biotechnology Inc F. Hoffmann-La Roche Ltd Novartis AG Takeda Pharmaceutical Co Ltd Boehringer Ingelheim International GmbH
Headquarters United States of America Switzerland Switzerland Japan Germany
City Los Angeles Basel Basel Chuo-Ku Ingelheim am Rhein
State/Province California - - Tokyo Rheinland-Pfalz
No. of Employees 185 103,605 76,057 49,095 53,000
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Alan H. Auerbach Chairman; President; Chief Executive Officer Executive Board 2011 53
Maximo F. Nougues Chief Financial Officer Senior Management 2018 54
Alvin Wong Chief Scientific Officer Senior Management 2021 70
Jeff J. Ludwig Chief Commercial Officer Senior Management 2020 57
Douglas Hunt Senior Vice President - Regulatory Affairs, Medical Writing and Project Management Senior Management 2018 58
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Puma Biotechnology Inc key executives to enhance your sales strategy Gain insight into Puma Biotechnology Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward